Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23
half life of glp 1 agonists GLP-1-based therapies for type 2 diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Patch With over 1 billion Frequency:1 month supply
With over 1 billion people worldwide living with obesity, GLP-1 adoption could transform obesity care and insurance. | Sonia Joseph
In the liver, it acts in glycogen storage, while in the pancreas it acts in the formation of new beta-cells and insulin biosynthesis, decreasing beta-cell apoptosis
Patch
Frequency:1 month supply
With obesity and type 2 diabetes reaching global epidemic levels at an accelerating rate, there is a significant unmet medical need for effective, scalable treatments
![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)
